The US Food and Drug Administration (FDA) has cleared the FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system for adults and children ages 4 years and older with diabetes. The ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...

Freestyle-Libre-14-day_MPR-Image The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for ...

FreeStyle Libre is a continuous glucose monitoring (CGM) system. It uses a sensor to read and check a person’s glucose levels. People with diabetes can use FreeStyle Libre to help manage the condition ...

FreeStyle Libre is a continuous glucose monitoring (CGM) system that allows a person to monitor their blood sugar levels in real time without finger pricks. It uses a sensor applied to the skin and a ...

The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

The world's first dual continuous glucose and ketone monitor is designed to help prevent diabetic ketoacidosis (DKA).

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...

Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...

Health care giant Abbott issued a warning impacting four million readers for glucose monitors after reports that devices were overheating and catching fire when patients used non-Abbott charging cords ...

CHICAGO (Reuters) - Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming ...